Please use this identifier to cite or link to this item:
Title: Multidrug-resistant tuberculosis
Author: Caminero, José A .
García-Basteiro, Alberto L.
Rendon, Adrian
Keywords: Tuberculosi
Resistència als medicaments
Drug resistance
Issue Date: 27-Jul-2019
Publisher: Elsevier
Abstract: The ideal number of drugs needed and treatment duration are crucial issues in the management of multidrug-resistant tuberculosis (MDR-TB). Thus, we read with interest the Article by the Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017,1 the results of which support our proposal,2 from 2015, to classify anti-tuberculosis drugs on the basis of their toxicity, and sterilising or bactericidal activity.
Note: Versió postprint del document publicat a:
It is part of: The Lancet, 2019, vol. 394, num. 10195, p. 298
Related resource:
ISSN: 0140-6736
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
CamineroJA_Lancet_2019_Correspondence.pdf66.23 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.